How are clinical innovations and unproven methods developed and introduced in western Nordic health-care systems? What is the legal and regulatory environment concerning unproven methods in medicine? What ethical principles should guide work on emerging treatments and experimentation in hospitals? These three questions were addressed in separate sessions in a day of fruitful discussions.
Among the keynote speakers were Professor Jonathan Kimmelman, Director of Biomedical Ethics Unit at McGill University, Professor Mette Hartlev from the University of Copenhagen, Dr. Jonathan Ives from the University of Bristol, Anne Sofie Boldsen who spoke from a patient perspective, and Professor Ingemar Engström from Örebro University and the Nordic Committee on Bioethics.